2019 August

Immuno-Oncology

Immuno-Oncology

The upsurge of research and development of Immuno-Oncology (IO) therapeutic drugs has been in full swing in recent years, which dominates the commanding point of public opinion in the field […]

Overview of Global approval of New drugs in July 2019

Overview of Global approval of New drugs in July 2019

In July 2019, the world’s first approval of new drugs was concentrated in the United States. The FDA (US Food and Drug Administration) approves three new molecular entity drugs (NME), […]

Hot spots in the field of drugs in July

Hot spots in the field of drugs in July

  Nat Med: a special intestinal bacteria, which is expected to reduce the risk of cardiovascular disease by 50 percent of the population. In 2007, scientists at institutions such as […]

Apixaban

Apixaban

In the past 2018, the global drug sales champion was still the macromolecular monoclonal antibody Humira (just short of $20 billion). The Top2 variety is a small molecular drug, but […]

Tyrosine kinase inhibitor dasatinib as a drug switch for CAR-T cells

Introduction of CAR-T T cells, also known as T lymphocytes, are a kind of human leukocytes, derived from bone marrow hematopoietic stem cells, mature in the thymus, and then migrate […]

Eight NMEs approved by FDA from January to June 2019

Eight NMEs approved by FDA from January to June 2019

The evaluation of drugs by FDA has always been the focus of pharmaceutical research all over the world, and the approval of NME (New molecular entity) to market is the […]